ZC3H14

Across TCGA pan-cancer cohorts, ZC3H14 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZC3H14 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ZC3H14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZC3H14 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, SCLC, and LIHC are the cancer types where ZC3H14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	9	view →
UCEC	DFS	Median	All	0.948	0.826	.016	6	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZC3H14–ACC (DFS)

Open the ACC breakdown →